Summary:
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)
Qualified Participants Must:
• Documented physician diagnosis of asthma for ≥12 month.
•
Documented history of at least one asthma exacerbation requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period with a history of exacerbations (at least one additional exacerbation within the past 36 months).
•
Weight >40 kg.
•
Participants requiring daily GINA 2021 step 4 or 5 treatment for at least 3 months and on a stable dose for at least 1 month before Screening Visit 1. ICS/LABA.
Qualified Participants May Receive:
$75 for each clinic visit